دورية أكاديمية
أعرض في EDS

Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets.

التفاصيل البيبلوغرافية
العنوان: Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets.
المؤلفون: Griffioen M; Department of Hematology, Leiden University Medical Center , Leiden , Netherlands., van Bergen CA; Department of Hematology, Leiden University Medical Center , Leiden , Netherlands., Falkenburg JH; Department of Hematology, Leiden University Medical Center , Leiden , Netherlands.
المصدر: Frontiers in immunology [Front Immunol] 2016 Mar 15; Vol. 7, pp. 100. Date of Electronic Publication: 2016 Mar 15 (Print Publication: 2016).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Print ISSN: 1664-3224 (Print) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مستخلص: Allogeneic stem cell transplantation (alloSCT) can be a curative treatment for hematological malignancies. Unfortunately, the desired anti-tumor or graft-versus-leukemia (GvL) effect is often accompanied with undesired side effects against healthy tissues known as graft-versus-host disease (GvHD). After HLA-matched alloSCT, GvL and GvHD are both mediated by donor-derived T-cells recognizing polymorphic peptides presented by HLA surface molecules on patient cells. These polymorphic peptides or minor histocompatibility antigens (MiHA) are produced by genetic differences between patient and donor. Since polymorphic peptides may be useful targets to manipulate the balance between GvL and GvHD, the dominant repertoire of MiHA needs to be discovered. In this review, the diversity of autosomal MiHA characterized thus far as well as the various molecular mechanisms by which genetic variants create immune targets and the role of cryptic transcripts and proteins as antigen sources are described. The tissue distribution of MiHA as important factor in GvL and GvHD is considered as well as possibilities how hematopoietic MiHA can be used for immunotherapy to augment GvL after alloSCT. Although more MiHA are still needed for comprehensive understanding of the biology of GvL and GvHD and manipulation by immunotherapy, this review shows insight into the composition and kinetics of in vivo immune responses with respect to specificity, diversity, and frequency of specific T-cells and surface expression of HLA-peptide complexes and other (accessory) molecules on the target cell. A complex interplay between these factors and their environment ultimately determines the spectrum of clinical manifestations caused by immune responses after alloSCT.
References: Front Immunol. 2014 Nov 06;5:529. (PMID: 25414699)
J Immunol. 2013 Apr 15;190(8):3869-77. (PMID: 23475216)
Hematology Am Soc Hematol Educ Program. 2011;2011:299-304. (PMID: 22160049)
Eur J Immunol. 2002 Oct;32(10):2748-58. (PMID: 12355426)
Nat Rev Immunol. 2007 May;7(5):340-52. (PMID: 17438575)
Leukemia. 2005 Jan;19(1):83-90. (PMID: 15526024)
J Clin Invest. 2005 Dec;115(12):3506-16. (PMID: 16322791)
Nat Rev Immunol. 2011 Nov 11;11(12):823-36. (PMID: 22076556)
Immunol Cell Biol. 2011 Mar;89(3):396-407. (PMID: 21301477)
Hematol J. 2003;4(5):315-20. (PMID: 14502255)
Leukemia. 2013 Mar;27(3):642-9. (PMID: 23079962)
Clin Cancer Res. 2008 Aug 15;14(16):5260-9. (PMID: 18698046)
Blood. 1999 Aug 15;94(4):1201-8. (PMID: 10438707)
Ann Med. 2014 Sep;46(6):384-96. (PMID: 24888385)
Cancer Immunol Immunother. 2008 Jun;57(6):849-57. (PMID: 18004563)
Cytometry A. 2008 Nov;73(11):1043-9. (PMID: 18561198)
Nat Med. 2002 Apr;8(4):410-4. (PMID: 11927949)
Clin Exp Immunol. 2011 Jan;163(1):1-10. (PMID: 20964638)
J Natl Cancer Inst. 2013 Aug 21;105(16):1172-87. (PMID: 23852952)
Haematologica. 2014 Dec;99(12):1854-9. (PMID: 25150256)
Blood. 2009 Oct 22;114(17 ):3684-92. (PMID: 19706888)
Science. 1995 Jun 9;268(5216):1476-80. (PMID: 7539551)
J Exp Med. 2008 Nov 24;205(12):2863-72. (PMID: 19001137)
Blood. 2007 Jan 1;109(1):365-73. (PMID: 16931626)
Biol Blood Marrow Transplant. 2012 Sep;18(9):1353-67. (PMID: 22796533)
Cancer Res. 2010 Nov 15;70(22):9073-83. (PMID: 21062987)
EMBO Rep. 2015 Dec;16(12 ):1640-55. (PMID: 26566663)
PLoS One. 2011;6(8):e23217. (PMID: 21858034)
Blood. 2008 Mar 15;111(6):3286-94. (PMID: 18178869)
Haematologica. 2007 Jan;92(1):72-80. (PMID: 17229638)
Science. 2006 Sep 8;313(5792):1444-7. (PMID: 16960008)
Blood. 2002 Dec 1;100(12):3877-86. (PMID: 12433695)
J Exp Med. 2001 Jan 15;193(2):195-206. (PMID: 11148223)
Haematologica. 2012 Aug;97(8):1196-204. (PMID: 22419570)
Bone Marrow Transplant. 2006 Jun;37(12):1129-34. (PMID: 16757974)
J Exp Med. 2003 Jun 2;197(11):1489-500. (PMID: 12771180)
Blood. 2010 May 13;115(19):3869-78. (PMID: 20071660)
Biol Blood Marrow Transplant. 2015 Jun;21(6):1000-7. (PMID: 25459643)
Best Pract Res Clin Haematol. 2008 Sep;21(3):543-57. (PMID: 18790454)
Blood. 1990 Feb 1;75(3):555-62. (PMID: 2297567)
Nat Rev Immunol. 2014 Jun;14(6):377-91. (PMID: 24830344)
Blood. 2008 Dec 1;112(12):4371-83. (PMID: 19029455)
Blood. 2007 Aug 1;110(3):1055-63. (PMID: 17409267)
Haematologica. 2015 Oct;100(10):e419-22. (PMID: 26069289)
Leukemia. 2014 Nov;28(11):2235-40. (PMID: 24781016)
Blood. 1991 Oct 15;78(8):2120-30. (PMID: 1912589)
Lancet. 2009 May 2;373(9674):1550-61. (PMID: 19282026)
Cancer Treat Rev. 2010 Nov;36(7):528-38. (PMID: 20381970)
Exp Hematol. 2003 Sep;31(9):743-51. (PMID: 12962719)
Immunol Res. 2008;41(1):56-78. (PMID: 17989941)
Blood. 2003 Jul 15;102(2):621-9. (PMID: 12663445)
J Immunol. 2002 Sep 15;169(6):3131-6. (PMID: 12218130)
Nat Med. 1999 Jul;5(7):839-42. (PMID: 10395333)
J Exp Med. 2003 May 19;197(10):1279-89. (PMID: 12743171)
PLoS One. 2014 Jan 15;9(1):e85198. (PMID: 24454818)
Haematologica. 2012 Aug;97(8):1205-8. (PMID: 22511490)
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3837-42. (PMID: 18316730)
PLoS One. 2011;6(6):e21266. (PMID: 21731686)
Science. 1998 Feb 13;279(5353):1054-7. (PMID: 9461441)
Nat Rev Immunol. 2015 Apr;15(4):203-16. (PMID: 25720354)
Mol Cell Proteomics. 2015 Mar;14(3):658-73. (PMID: 25576301)
J Immunol. 2001 Sep 15;167(6):3223-30. (PMID: 11544309)
Blood. 2010 Jun 10;115(23):4923-33. (PMID: 20203263)
Clin Cancer Res. 2015 May 1;21(9):2177-86. (PMID: 25589627)
Expert Rev Hematol. 2014 Oct;7(5):671-81. (PMID: 25186852)
Science. 2015 Apr 3;348(6230):69-74. (PMID: 25838375)
PLoS One. 2011;6(6):e21699. (PMID: 21738768)
Tissue Antigens. 2014 Oct;84(4):374-60. (PMID: 25262921)
Blood. 2007 May 1;109(9):4089-96. (PMID: 17234742)
Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S33-8. (PMID: 21195308)
Blood. 2006 Jun 15;107(12):4954-60. (PMID: 16497972)
J Exp Med. 1999 Jan 18;189(2):301-8. (PMID: 9892612)
Br J Haematol. 2006 Aug;134(4):406-16. (PMID: 16822283)
Clin Cancer Res. 2009 Dec 1;15(23):7137-43. (PMID: 19934307)
Blood. 2013 Sep 12;122(11):1863-72. (PMID: 23878143)
Blood. 2012 Oct 4;120(14):2796-806. (PMID: 22859606)
Blood. 2013 Sep 12;122(11):1963-73. (PMID: 23777765)
J Immunother. 2009 Jul-Aug;32(6):539-51. (PMID: 19483655)
J Clin Med. 2015 Mar 19;4(3):488-503. (PMID: 26239251)
Blood. 2009 May 21;113(21):5041-8. (PMID: 18809759)
J Leukoc Biol. 2014 Apr;95(4):551-62. (PMID: 24532645)
Blood. 2006 May 1;107(9):3779-86. (PMID: 16391015)
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2742-7. (PMID: 12601144)
Cytotherapy. 2008;10(2):108-15. (PMID: 18368589)
فهرسة مساهمة: Keywords: T-lymphocytes; allogeneic stem cell transplantation; donor lymphocyte infusion; graft-versus-host disease; graft-versus-leukemia reactivity; hematological malignancy; immunotherapy; minor histocompatibility antigens
تواريخ الأحداث: Date Created: 20160326 Date Completed: 20160325 Latest Revision: 20181113
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC4791598
DOI: 10.3389/fimmu.2016.00100
PMID: 27014279
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-3224
DOI:10.3389/fimmu.2016.00100